|

Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

RECRUITINGSponsored by University of Aarhus
Actively Recruiting
SponsorUniversity of Aarhus
Started2020-10-01
Est. completion2026-09
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04514965

Summary

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* PBC patient offered bezafibrate treatment

Exclusion Criteria:

* patient age under 18
* life expectancy less than 6 months
* known cancer
* planned liver transplantation within 6 months
* other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)

Conditions2

Liver DiseasePrimary Biliary Cirrhosis

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.